JP2022513586A5 - - Google Patents
Info
- Publication number
- JP2022513586A5 JP2022513586A5 JP2021523759A JP2021523759A JP2022513586A5 JP 2022513586 A5 JP2022513586 A5 JP 2022513586A5 JP 2021523759 A JP2021523759 A JP 2021523759A JP 2021523759 A JP2021523759 A JP 2021523759A JP 2022513586 A5 JP2022513586 A5 JP 2022513586A5
- Authority
- JP
- Japan
- Prior art keywords
- population
- cells
- cancer
- genetically engineered
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862756723P | 2018-11-07 | 2018-11-07 | |
| US62/756,723 | 2018-11-07 | ||
| PCT/IB2019/059586 WO2020095249A1 (en) | 2018-11-07 | 2019-11-07 | Anti-liv1 immune cell cancer therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022513586A JP2022513586A (ja) | 2022-02-09 |
| JP2022513586A5 true JP2022513586A5 (https=) | 2022-11-15 |
| JP7471289B2 JP7471289B2 (ja) | 2024-04-19 |
Family
ID=68582073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523759A Active JP7471289B2 (ja) | 2018-11-07 | 2019-11-07 | 抗ｌｉｖ１免疫細胞癌療法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12304968B2 (https=) |
| EP (1) | EP3877419A1 (https=) |
| JP (1) | JP7471289B2 (https=) |
| KR (1) | KR20210089707A (https=) |
| CN (1) | CN113015750A (https=) |
| AU (1) | AU2019376903A1 (https=) |
| BR (1) | BR112021008082A2 (https=) |
| CA (1) | CA3118824A1 (https=) |
| CO (1) | CO2021006493A2 (https=) |
| EA (1) | EA202191257A1 (https=) |
| IL (1) | IL282531A (https=) |
| MX (1) | MX2021005395A (https=) |
| PH (1) | PH12021551036A1 (https=) |
| SG (1) | SG11202104523PA (https=) |
| WO (1) | WO2020095249A1 (https=) |
| ZA (1) | ZA202102740B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2648752B1 (en) | 2010-12-06 | 2017-02-15 | Seattle Genetics, Inc. | Humanized antibodies to liv-1 and use of same to treat cancer |
| ES2836743T3 (es) * | 2014-06-02 | 2021-06-28 | Us Health | Receptores de antígeno quiméricos que seleccionan como diana CD-19 |
| MX2018010847A (es) | 2016-03-15 | 2019-07-04 | Seattle Genetics Inc | Terapia combinada mediante el uso de un conjugado de anticuerpo-farmaco de liv1 (liv1-adc) y agente quimioterapeutico. |
| KR20220128363A (ko) * | 2019-12-24 | 2022-09-20 | 제이제이피 바이오로직스 에스피. 제트 오.오. | 항-인간 hvem(tnfrsf14) 항체 및 그의 용도 |
| KR20230122618A (ko) | 2020-12-21 | 2023-08-22 | 알로젠 테라퓨틱스 인코포레이티드 | 프로테아제 활성화 cd45-게이트 car |
| CA3204417A1 (en) | 2021-01-29 | 2022-08-04 | Allogene Therapeutics, Inc. | Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products |
| WO2023111913A1 (en) | 2021-12-15 | 2023-06-22 | Crispr Therapeutics Ag | Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption |
| CA3261440A1 (en) | 2022-07-29 | 2024-02-01 | Allogene Therapeutics, Inc. | MODIFIED CELLS WITH REDUCED GENE EXPRESSION TO MITIGATE RECOGNITION BY IMMUNE CELLS |
| IL322565A (en) | 2023-02-07 | 2025-10-01 | Lanova Medicines Ltd | Antibodies targeting liv-1 and their uses |
| AU2024372734A1 (en) | 2023-10-30 | 2026-04-16 | Allogene Therapeutics, Inc. | Engineered cells |
| WO2025162207A1 (zh) * | 2024-01-31 | 2025-08-07 | 上海复宏汉霖生物技术股份有限公司 | 抗liv1抗体及使用方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| KR20030032922A (ko) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | 세포의 동시 자극 및 농축 |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
| JP2005500061A (ja) | 2001-08-20 | 2005-01-06 | ザ スクリップス リサーチ インスティテュート | Ｃｎｎについての亜鉛フィンガー結合ドメイン |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| WO2011072246A2 (en) | 2009-12-10 | 2011-06-16 | Regents Of The University Of Minnesota | Tal effector-mediated dna modification |
| EP2648752B1 (en) * | 2010-12-06 | 2017-02-15 | Seattle Genetics, Inc. | Humanized antibodies to liv-1 and use of same to treat cancer |
| JP6681837B2 (ja) * | 2014-03-11 | 2020-04-15 | セレクティスＣｅｌｌｅｃｔｉｓ | 同種移植に適合するｔ細胞を作製するための方法 |
| US20170335331A1 (en) | 2014-10-31 | 2017-11-23 | The Trustees Of The University Of Pennsylvania | Altering Gene Expression in CART Cells and Uses Thereof |
| EP3389677B1 (en) * | 2015-12-18 | 2024-06-26 | Sangamo Therapeutics, Inc. | Targeted disruption of the t cell receptor |
| MX2018010847A (es) | 2016-03-15 | 2019-07-04 | Seattle Genetics Inc | Terapia combinada mediante el uso de un conjugado de anticuerpo-farmaco de liv1 (liv1-adc) y agente quimioterapeutico. |
| KR102546839B1 (ko) | 2016-08-03 | 2023-06-23 | 워싱턴 유니버시티 | 키메라 항원 수용체를 이용한 t 세포 악성종양의 치료를 위한 car-t 세포의 유전자 편집 |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| EP3529265A2 (en) * | 2016-10-19 | 2019-08-28 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| EP3548055A4 (en) * | 2016-12-02 | 2020-08-19 | University of Southern California | SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE |
-
2019
- 2019-11-07 WO PCT/IB2019/059586 patent/WO2020095249A1/en not_active Ceased
- 2019-11-07 CA CA3118824A patent/CA3118824A1/en active Pending
- 2019-11-07 AU AU2019376903A patent/AU2019376903A1/en not_active Withdrawn
- 2019-11-07 US US16/677,267 patent/US12304968B2/en active Active
- 2019-11-07 SG SG11202104523PA patent/SG11202104523PA/en unknown
- 2019-11-07 US US17/291,198 patent/US20210292429A1/en not_active Abandoned
- 2019-11-07 EP EP19804870.4A patent/EP3877419A1/en active Pending
- 2019-11-07 CN CN201980073282.9A patent/CN113015750A/zh active Pending
- 2019-11-07 BR BR112021008082-1A patent/BR112021008082A2/pt not_active Application Discontinuation
- 2019-11-07 KR KR1020217017024A patent/KR20210089707A/ko not_active Withdrawn
- 2019-11-07 EA EA202191257A patent/EA202191257A1/ru unknown
- 2019-11-07 MX MX2021005395A patent/MX2021005395A/es unknown
- 2019-11-07 JP JP2021523759A patent/JP7471289B2/ja active Active
-
2021
- 2021-04-21 IL IL282531A patent/IL282531A/en unknown
- 2021-04-23 ZA ZA2021/02740A patent/ZA202102740B/en unknown
- 2021-05-05 PH PH12021551036A patent/PH12021551036A1/en unknown
- 2021-05-20 CO CONC2021/0006493A patent/CO2021006493A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022513586A5 (https=) | ||
| JP2022509017A5 (https=) | ||
| JP2024097924A5 (https=) | ||
| JP2022512882A5 (https=) | ||
| JP2021522820A5 (https=) | ||
| JP6664528B2 (ja) | Ｃｌｄ１８ａ２標的免疫エフェクター細胞及びその調製方法と使用 | |
| IL278348B1 (en) | Methods and compositions for treating cancer | |
| CA2951355C (en) | Car-expressing nk-92 cells as cell therapeutic agents | |
| AU2023201162A1 (en) | Compositions and methods for immunooncology | |
| JP2019531056A5 (https=) | ||
| JP2020519641A5 (https=) | ||
| US20250074965A1 (en) | Anti-ptk7 immune cell cancer therapy | |
| JP7471289B2 (ja) | 抗ｌｉｖ１免疫細胞癌療法 | |
| FI3515487T3 (fi) | Bispesifisiä anti-MUC16-CD3-vasta-aineita ja anti-MUC16-lääkekonjugaatteja | |
| US20170159025A1 (en) | Nucleic acid for coding chimeric antigen receptor protein and t lymphocyte for expression of chimeric antigen receptor protein | |
| ES2871400T3 (es) | Células inmunitarias deficientes en SUV39H1 | |
| JP2018522072A5 (https=) | ||
| JP2021506243A5 (https=) | ||
| JP2019525771A5 (https=) | ||
| JP2017537620A5 (https=) | ||
| JP2011157397A5 (https=) | ||
| JP2016508725A5 (https=) | ||
| Gacerez et al. | Chimeric antigen receptors with human scFvs preferentially induce T cell anti-tumor activity against tumors with high B7H6 expression | |
| Lee et al. | Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models | |
| JP2021534784A5 (https=) |